Anzeige
Mehr »
Login
Montag, 23.12.2024 Börsentäglich über 12.000 News von 679 internationalen Medien
Die erste börsennotierte Gesellschaft, die auf das gemeinsame Wachstum von Solana, XRP und Dogecoin setzt!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3D7B9 | ISIN: US92941V3087 | Ticker-Symbol: 26JB
NASDAQ
19.12.24
19:43 Uhr
2,450 US-Dollar
+0,060
+2,51 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
VYNE THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
VYNE THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur VYNE THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoVYNE Therapeutics Inc. - S-8, Securities to be offered to employees in employee benefit plans-
12.12.VYNE Therapeutics Inc. - 8-K, Current Report-
07.11.VYNE Therapeutics Inc.: VYNE Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update91VYN201 Phase 2b vitiligo trial exceeds enrollment target; Expected to be fully enrolled in December 2024 with top-line results on track for mid-2025Reported positive first-in-human Phase 1a SAD data...
► Artikel lesen
07.11.VYNE Therapeutics Inc. - 8-K, Current Report-
12.09.VYNE Therapeutics Inc.: VYNE Therapeutics Announces Positive Phase 1a SAD Data for VYN202, a Novel BD2-Selective BET Inhibitor120VYN202 was generally well tolerated with no drug-related adverse eventsPharmacokinetic results demonstrated dose-dependent exposure of VYN202 in blood Pharmacodynamic activity observed on target engagement...
► Artikel lesen
VYNE THERAPEUTICS Aktie jetzt für 0€ handeln
12.09.VYNE Therapeutics Inc. - 8-K, Current Report1
15.08.VYNE Therapeutics stock maintains Buy rating and price target2
15.08.VYNE Therapeutics GAAP EPS of -$0.22 beats by $0.01, revenue of $0.2M beats by $0.09M1
14.08.VYNE Therapeutics Inc.: VYNE Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update136Initiated Phase 2b trial of VYN201 in nonsegmental vitiligo, with top-line results expected in mid-2025Phase 1a SAD/MAD trial of VYN202 progressing, with data from the SAD and MAD portions expected...
► Artikel lesen
14.08.VYNE Therapeutics Inc. - 8-K, Current Report1
26.06.VYNE Therapeutics Inc.: VYNE Therapeutics to Participate in Leerink Partners Therapeutics Forum1
13.06.VYNE Therapeutics Inc.: VYNE Therapeutics Announces Dosing of First Participants in Phase 1a Trial of Novel BD2-Selective BET Inhibitor VYN202120VYN202 has been designed to achieve class-leading potency and BD2-selectivity Trial will evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of VYN202 in healthy volunteers; top-line...
► Artikel lesen
05.06.VYNE Therapeutics Inc.: VYNE Therapeutics Announces Dosing of First Subject in Phase 2b Vitiligo Trial of Novel BET Inhibitor VYN201132Trial will evaluate once-daily VYN201 gel in subjects with either active or stable nonsegmental vitiligo Top-line data from the 24-week double-blind portion of the trial expected in mid-2025 ...
► Artikel lesen
29.02.VYNE Therapeutics Inc.: VYNE Reports 2023 Fourth Quarter and Year-End Financial Results and Provides Business Update2952023 was a transformative year for VYNE, marked by the achievement of clinical proof-of-concept for VYN201 in vitiligo and a successful financing with a syndicate of leading institutional investorsAnticipate...
► Artikel lesen
10.01.VYNE Therapeutics Inc.: VYNE Therapeutics Announces Positive Biomarker Data from Successful Phase 1b Trial of VYN201 for the Treatment of Vitiligo426VYN201 demonstrated positive effect on key biomarkers relevant to vitiligo Data supports VYN201's rapid onset of action and previously announced positive clinical resultsProgram is on track for Phase...
► Artikel lesen
15 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1